Biomarkers as prognostic factors in endometrial cancer. by Dobrzycka, Bożena & Terlikowski, Sławomir J
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(3): 319 (319-322) 
10.2478/v10042-10-0061-8
Introduction
Cancer of the uterus is the seventh most commonly
diagnosed cancer that occurs in women, with 189,000
new cases and 45,000 deaths occurring worldwide
each year. About 60% of these occur in more devel-
oped countries. The highest incidence rates are in the
USA and Canada. The age-adjusted incidence rate in
the USA was 23.3 per 100,000 women per year [1]. In
other regions, with age-standardized rates in excess of
10 per 100,000 include Europe, Australia and New
Zealand, the southern part of South America, and the
Pacific Island nations. Low rates occur in Africa
(Uganda 3.3 per 100,000) and Asia (China 3.8 per
100,000) [2]. In Poland, the age-adjusted incidence
was 13.7 per 100,000 women per year [3]. 
Etiology and risk factors
Endometrial cancers are known to be heterogeneous
with respect to the expression of biochemical markers,
ploidy, degree of differentiation, immunogenicity [4].
The disease is rare before the age of 40, and <20%
occur before menopause [5]. Around 5-10% of
endometrial carcinomas have a hereditary basis, with
hereditary non-polyposis colorectal cancer being the
most common cause [6]. The risk factors relate to hor-
monal stimulation of the endometrium, such as unop-
posed estrogen treatment, polycystic ovarian disease
and estrogen-producing tumors. Overweight is present
in 50% with endometrial carcinoma, and the risk is
linked to disturbances in hormone metabolism related
to obesity. Nulliparity is a risk factor for endometrial
cancer, and breast cancer patients treated with tamox-
ifen have a six- to eight-fold increased risk [4,7].
Tumor biology and biomarkers
The endometrium undergoes structural modification
and changes in specialised cells in response to fluctua-
tions of estrogen and progesterone during the menstru-
al cycle. Long-lasting unopposed estrogen exposure
leads to endometrial hyperplasia, which increases the
chance of development of type I endometrial cancer.
The molecular basis of this process is still not known,
since the involvement of only a minority of factors is
reproducible [8-11]. The development of endometrial
cancer is characterized also by self-sufficiency in
growth signals, insensitivity to growth inhibition,
apoptosis, angiogenesis, invasion and metastasis [12]. 
Oncogenes
Activation of proto-oncogenes is a feature of many
malignancies and, not surprisingly, there have been
numerous searches for oncogene mutations in endome-
trial cancer [13]. The proto-oncogenes, HER-2/neu and
EGFR, both members of the epidermal growth factor
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receptor tyrosine kinase (RTK) family, have an impor-
tant role in regulating cell growth and differentiation,
although it is not clear how a specific signalling pathway
corresponds to biological and clinical response [14].
HER-2/neu overexpression is reported in 9-30%
endometrial cancers and has been associated with a
metastatic phenotype and poor survival in type II
endometrial cancer [15]. KRAS encodes a member pro-
tein of the small GTPase superfamily and is involved in
signal transduction pathways between cell surface recep-
tors and the nucleus. KRAS mutations have been found
in 10-30% of endometrial carcinomas, predominantly in
type I tumors [8,9,16,17]. The PIK3CA (p110α catalytic
subunit of PI3K) gene locates on chromosome 3q26.32.
Phosphatidylinositol-3-kinase (PI3K) is heterodimeric
lipid kinase consisting of a catalytic subunit (p110) and a
regulatory subunit (p85) in PI3K/AKT signaling path-
way. This pathway is frequently activated in endometri-
al carcinoma through various genetic alterations and
their combinations. Activation of PI3K produces the sec-
ond messenger PIP3 which subsequently activates vari-
ous down-stream pathways such as AKT [4,16]. Muta-
tions in PIK3CA occur in 24-36% endometrial cancers
and are coexisting with PTEN mutations in 14-26% [18].
Although molecularly targeted therapies have been
effective in some cancer types, no targeted therapy is
approved for use in endometrial cancer. The recent iden-
tification of activating mutations in fibroblast growth
factor receptor 2 (FGFR2) in endometrial tumors has
generated a new avenue for the development of targeted
therapeutic agents. The majority of the mutations identi-
fied are identical to germline mutations in FGFR2 and
FGFR3 [19]. Mutations that predominantly occur in the
type I of endometrial cancer, are mutually exclusive with
KRAS mutation [8,17,20].
Tumor suppressor gene defects
A number of tumor suppressor genes have been shown
to contribute to the genesis of endometrial cancers. The
genes code for proteins inhibiting tumor growth. When
mutated, they become inactive and growth is allowed
[21]. Endometrial cancers, from a molecular viewpoint
also, resemble proliferative rather than secretory
endometrium. PTEN encodes a phosphatase, antagoniz-
ing the PI3K/AKT pathway. Decreased PTEN activity
causes increased cell proliferation, cell survival and
angiogenesis, and is involved in cell adhesion and migra-
tion. PTEN can be inactivated by mutations, deletions or
promoter hypermethylation. PTEN mutations are report-
ed in 25-83% of endometrial cancers, more frequently in
type I [12,22]. The P53 gene regulates cell cycle, apop-
tosis and differentiation. P53 mutations have been found
in 10-20% of endometrial carcinomas, while p53 protein
overexpression is present in 15-30%. Overexpression of
p53 is more frequent in type II than type I tumors
[11,37,38]. P53 mutations are considered to be an early
event in type II tumors (80-90%) and a late event for type
I tumors (5-10%) [8,16,22]. Alterations of the CDKN2A
(p16) gene have been involved in tumor development in
several organs. The CDKN2A gene encodes 2 proteins,
p16 and ARF. The p16 protein encoded by the CDKN2A
gene has been identified as a tumor suppressor. In
endometrial carcinoma, loss of protein expression varies
from 14 to 74% in different studies. The underlying
mechanism of pl6 inactivation in these tumors is
unknown, because mutations, deletions and promoter
methylation only occur in 2-6% [23]. Loss of p16
expression is correlated with KRAS and P53 mutations
and is associated with high stage, high grade, and poor
survival [13].
Mismatch repair genes (MMR) and
microsatellite instability (MSI)
Microsatellite instability (MSI) is a condition manifested
by damaged DNA because of defects in normal DNA
repair process. Mammalian mismatch repair (MMR)
genes encode for nine proteins (MLH1, MLH3,
PMS1,PMS2, MSH2, MSH3, MSH4, MSH5, and
MSH6) that interact with each other to form complexes
and heterodimers that mediate distinct functions in
MMR-related system. This repair process plays a central
role in promoting genetic stability by repairing DNA
replication errors, inhibiting recombination between
non-identical DNA sequences and participating in
responses to DNA damage [16,24]. MSI has later been
found in 20-30% of endometrial carcinomas, due to epi-
genetic inactivation through hypermethylation of the
MLHl promoter in most cases. MSI has been reported to
be more common in type I than type II cancers [4,25].
DNA ploidy
Approximately 67% of type I endometrial carcinomas
are diploid, as evaluated by flow cytometry. In con-
trast, 55% of the type II carcinomas exhibit nondiploid
DNA patterns. Diploid tumors are usually low-grade
type I carcinomas with only superficial invasion, and
are associated with longer survival than aneuploid car-
cinomas. Differences in disease-free survival for stage
I tumors have been as significant as 94% for diploid
carcinomas versus 64% for aneuploid carcinomas.
Aneuploid tumors are present in 20-35% of endome-
trial carcinomas, associated with a high stage, a high
grade, type II and deep myometrial invasion [26,27].
Steroid receptors
The presence of the classic steroid receptors ERα and
PR-A have correlated with stage, grade and survival in
several studies. Additionally, it is thought that the ER and
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PR status constitutes independent prognostic factors [28].
However, PR, in contrast to ER, is suggested to be a more
predictive factor of disease-free survival [29], while some
authors have also reported that the presence of steroid
receptors does not constitute an independent prognostic
factor for endometrial cancer [30]. Therefore, the useful-
ness of the determination of receptor status in endometri-
al cancer patients is still controversially discussed. 
Angiogenesis
Angiogenesis has been shown to be a critical aspect of
endometrial cancer growth and metastasis [31]. The
induction of angiogenesis by a tumor is a controlled
process, influenced by angiogenic and angiostatic fac-
tors which involves a complex interaction between
tumor and endothelial cells. Among many reported
angiogenic factors, vascular endothelial growth factor
(VEGF) is the most powerful endothelial-cell-specific
mitogen that plays a key role in the complicated
process of angiogenesis [32]. VEGF strong positive
tumors showed a poorer prognosis than VEGF nega-
tive tumors. There was a trend towards an association
between the strong positive expression of VEGF and
5-year disease-free survival. These results suggest that
VEGF may be an important, clinically relevant, induc-
er of angiogenesis in type I endometrial cancer [33].
Lymphangiogenic factors have recently been studied
in endometrial carcinoma, associating aggressive phe-
notype with the presence of lymphatic vessel infiltra-
tion and high lymphatic vessel density [34,35]. 
Invasion and metastasis
Invasion and metastasis are the most insidious and life-
threatening aspects of cancer. Tumors of comparable
size and histology can have widely divergent metasta-
tic potential, depending on their genotype and local
environmental influences. Metastatic potential is influ-
enced by the local microenvironment, angiogenesis,
stroma-tumor interactions, and elaboration of
cytokines by the local tissue, and more significantly by
its molecular phenotype [36,37]. Specific genetic
alterations in cellular adhesion molecules, among them
the cadherins and catenins, are important for such
tumor-stroma and tumor-vascular interactions [38].
Changes in cadherin expression, also termed the "cad-
herin switch", have been associated with type II
endometrial cancer [39]. Mutations in the β-catenin
and connexin 26 gene lead to high protein expression,
and were more common in type I tumors [40,41].
Cancer stem cells and endometrial cancer
Many features of carcinoma can be explained by the
stem cell concept, including clonal origin and hetero-
geneity of tumors, some associated with transit ampli-
fying (TA) cells or progenitors, the mesenchymal
influence on cancer behaviour, the local formation of
precancerous lesions and the plasticity of tumor cells
[42]. Only a small proportion of the tumor actually
comprises cancer stem cells about 0.02-1%. Thus,
cancer stem cells act as precursor cells that produce the
proliferating, more differentiated cancer cells killed by
chemotherapy or radiation. Cancer stem cells differ
from normal tissue stem cells in that their proliferation
is no longer controlled by the neighbouring cells of the
stem cell niche [43]. As endometrial stem/progenitors
cells become better characterized, their role in
endometrial cancer can be assessed [44].
Dualistic model of endometrial carcinoma
Bokhman first described the pathogenetic classifica-
tion of two different types of endometrial carcinoma,
designated as type I and type II carcinomas, according
to the determination of biological properties of the
tumor, its clinical course, and the prognosis of the dis-
ease [45]. Molecular profiling reveals genetic changes
in endometrial cancer that support the dualistic model,
in which type I accounts for around 80%, usually of
endometrioid type, estrogen-dependent, low grade
lesions and type II non-estrogen dependent, poorly dif-
ferentiated, not associated with estrogenic risk factors
and with a poor prognosis. The molecular changes in
type I tumors include mutations in PTEN, PIK3CA,
KRAS, and β-catenin, along with microsatellite instabil-
ity, whereas type II are characterized by genetic alter-
ations in P53, HER2/neu, p16, and E-cadherin. In addi-
tion, P53 mutations may play an important role in
tumorigenesis of type II tumor. These molecular
changes can help in the diagnosis of endometrial neo-
plasms, as well as form the basis of molecular targeted
therapy [8,9,10,16,17].
Conclusions
Newer tumor markers and prognostic indicators are
needed to help determine which patients would benefit
from either adjuvant treatment or more aggressive pri-
mary treatment. Type I cancers are associated with muta-
tions in KRAS, PIK3CA and β-catenin oncogenes, PTEN
tumor suppressor gene and defects in DNA mismatch
repair; by contrast, those of type II are associated with
mutations in P53 gene, E-cadherin tumor suppressor
gene, HER-2/neu and p16 expression and most are non-
diploid. The clinical value of these markers for prognos-
tication in a routine diagnostic setting, and predicting
response to targeted treatment, remains to be settled. 
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